EA013878B1 - Лиганды, имеющие специфичность связывания в отношении рецептора эпидермального фактора роста (egfr) и/или сосудистого эндотелиального фактора роста (vegf), и способы их применения - Google Patents

Лиганды, имеющие специфичность связывания в отношении рецептора эпидермального фактора роста (egfr) и/или сосудистого эндотелиального фактора роста (vegf), и способы их применения Download PDF

Info

Publication number
EA013878B1
EA013878B1 EA200801172A EA200801172A EA013878B1 EA 013878 B1 EA013878 B1 EA 013878B1 EA 200801172 A EA200801172 A EA 200801172A EA 200801172 A EA200801172 A EA 200801172A EA 013878 B1 EA013878 B1 EA 013878B1
Authority
EA
Eurasian Patent Office
Prior art keywords
zeo
oom16
binding
binding specificity
ecec
Prior art date
Application number
EA200801172A
Other languages
English (en)
Russian (ru)
Other versions
EA200801172A1 (ru
Inventor
Ольга Игнатович
Стив Холмс
Роланд Бекманн
Хайкун Лиу
Рудольф М.Т. Де Вильдт
Лорен С. Джесперс
Майкл Стьюард
Армин Сепп
Малгорзата Пьюпекка
Original Assignee
Домантис Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Домантис Лимитед filed Critical Домантис Лимитед
Publication of EA200801172A1 publication Critical patent/EA200801172A1/ru
Publication of EA013878B1 publication Critical patent/EA013878B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
EA200801172A 2005-12-06 2006-12-05 Лиганды, имеющие специфичность связывания в отношении рецептора эпидермального фактора роста (egfr) и/или сосудистого эндотелиального фактора роста (vegf), и способы их применения EA013878B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US74299205P 2005-12-06 2005-12-06
US75835506P 2006-01-11 2006-01-11
PCT/GB2006/004559 WO2007066106A1 (en) 2005-12-06 2006-12-05 Ligands that have binding specificity for egfr and/or vegf and methods of use therefor

Publications (2)

Publication Number Publication Date
EA200801172A1 EA200801172A1 (ru) 2008-12-30
EA013878B1 true EA013878B1 (ru) 2010-08-30

Family

ID=37820653

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200801172A EA013878B1 (ru) 2005-12-06 2006-12-05 Лиганды, имеющие специфичность связывания в отношении рецептора эпидермального фактора роста (egfr) и/или сосудистого эндотелиального фактора роста (vegf), и способы их применения

Country Status (13)

Country Link
US (2) US20100056439A1 (https=)
EP (1) EP1966242A1 (https=)
JP (1) JP2009518024A (https=)
KR (1) KR20080077261A (https=)
AU (1) AU2006323412A1 (https=)
BR (1) BRPI0619463A2 (https=)
CA (1) CA2632417A1 (https=)
CR (1) CR10024A (https=)
EA (1) EA013878B1 (https=)
MA (1) MA30021B1 (https=)
NO (1) NO20082386L (https=)
TW (1) TW200804425A (https=)
WO (1) WO2007066106A1 (https=)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9321832B2 (en) * 2002-06-28 2016-04-26 Domantis Limited Ligand
US7696320B2 (en) * 2004-08-24 2010-04-13 Domantis Limited Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor
GB0621513D0 (en) * 2006-10-30 2006-12-06 Domantis Ltd Novel polypeptides and uses thereof
GB0724331D0 (en) * 2007-12-13 2008-01-23 Domantis Ltd Compositions for pulmonary delivery
US20090304719A1 (en) 2007-08-22 2009-12-10 Patrick Daugherty Activatable binding polypeptides and methods of identification and use thereof
US20090148905A1 (en) * 2007-11-30 2009-06-11 Claire Ashman Antigen-binding constructs
EP2220115A2 (en) * 2007-12-13 2010-08-25 Glaxo Group Limited Polypeptides, antibody variable domains & antagonists
US8454960B2 (en) * 2008-01-03 2013-06-04 The Scripps Research Institute Multispecific antibody targeting and multivalency through modular recognition domains
KR101658247B1 (ko) 2008-01-03 2016-09-22 더 스크립스 리서치 인스티튜트 모듈 인식 도메인을 통한 항체 표적화
SG189682A1 (en) * 2008-03-31 2013-05-31 Glaxo Group Ltd Drug fusions and conjugates
WO2009127691A1 (en) 2008-04-17 2009-10-22 Ablynx N.V. Peptides capable of binding to serum proteins and compounds, constructs and polypeptides comprising the same
US9198952B2 (en) 2008-09-22 2015-12-01 The Brigham And Women's Hospital, Inc. Compositions of and methods of using ligand dimers
AU2009306424A1 (en) * 2008-10-21 2010-04-29 Domantis Limited Ligands that have binding specificity for DC-SIGN
KR20110091777A (ko) * 2008-11-26 2011-08-12 글락소 그룹 리미티드 폴리펩티드, 항체 가변 도메인 및 길항제
RU2636046C2 (ru) 2009-01-12 2017-11-17 Сайтомкс Терапьютикс, Инк Композиции модифицированных антител, способы их получения и применения
AU2010215479B2 (en) * 2009-02-19 2015-01-22 Glaxo Group Limited Improved anti-TNFR1 polypeptides, antibody variable domains & antagonists
AU2010215761B2 (en) 2009-02-23 2017-04-06 Cytomx Therapeutics, Inc Proproteins and methods of use thereof
JP5901517B2 (ja) * 2009-05-28 2016-04-13 グラクソ グループ リミテッドＧｌａｘｏ Ｇｒｏｕｐ Ｌｉｍｉｔｅｄ 抗原結合性タンパク質
WO2011006915A2 (en) * 2009-07-16 2011-01-20 Glaxo Group Limited Improved anti-serum albumin binding single variable domains
EP2531523A1 (en) 2010-02-05 2012-12-12 Ablynx N.V. Peptides capable of binding to serum albumin and compounds, constructs and polypeptides comprising the same
WO2011119836A1 (en) 2010-03-24 2011-09-29 Massachusetts Institute Of Technology Methods and compositions for cardioprotection and cardioregeneration
WO2012009705A1 (en) 2010-07-15 2012-01-19 Zyngenia, Inc. Ang-2 binding complexes and uses thereof
WO2012022703A2 (en) * 2010-08-20 2012-02-23 Glaxo Group Limited Improved anti-serum albumin binding variants
AU2011333738A1 (en) * 2010-11-24 2013-07-11 Glaxo Group Limited Multispecific antigen binding proteins targeting HGF
EP2714738B1 (en) 2011-05-24 2018-10-10 Zyngenia, Inc. Multivalent and monovalent multispecific complexes and their uses
EP2777707A1 (en) 2013-03-11 2014-09-17 Wake Forest University Health Sciences Method of Treating Brain Tumors
US10150800B2 (en) 2013-03-15 2018-12-11 Zyngenia, Inc. EGFR-binding modular recognition domains
CN115160441A (zh) * 2013-09-26 2022-10-11 埃博灵克斯股份有限公司 双特异性纳米抗体
JP7001474B2 (ja) 2015-01-21 2022-01-19 インヒブルクス，インコーポレイティド 非免疫原性単一ドメイン抗体
EP3253790A4 (en) * 2015-02-06 2018-07-25 University of Maryland, Baltimore Tetra-specific, octameric binding agents and antibodies against clostridium difficile toxin a and toxin b for treatment of c. difficile infection
CA2991634C (en) 2015-07-16 2026-03-17 Inhibrx Biosciences, Inc. Multivalent and multispecific dr5-binding fusion proteins
KR101685532B1 (ko) * 2016-04-26 2016-12-13 한국프라임제약주식회사 혈관내피성장인자 수용체 융합단백질
CN111936516B (zh) 2018-03-19 2023-03-03 上海药明生物技术有限公司 新型抗egfr抗体多肽
JP7698581B2 (ja) 2019-03-29 2025-06-25 グリーン・クロス・コーポレイション 抗メソテリン抗体、抗ｃｄ３抗体又は抗ｅｇｆｒ抗体を含む融合タンパク質、それを含む二重特異性又は三重特異性抗体、及びその使用
WO2022047169A1 (en) * 2020-08-28 2022-03-03 Trustees Of Boston University Engineered extracellular receptor constructs and uses thereof
CN115724968B (zh) * 2021-08-27 2023-08-08 三优生物医药(上海)有限公司 Vegf结合分子及其用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2177950C2 (ru) * 1996-10-25 2002-01-10 Нексстар Фармасьютикалз, Инк. Комплексы нуклеиновых кислот - лигандов сосудистого эндотелиального фактора роста (vegf)
RU2003114746A (ru) * 2000-10-20 2004-12-20 Тугаи Сейяку Кабусики Кайся Модифицированное агонистическое антитело

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT699237E (pt) * 1994-03-17 2003-07-31 Merck Patent Gmbh Fvs de cadeia anti-egfr e anticorpos anti-egfr
KR100816621B1 (ko) * 1997-04-07 2008-03-24 제넨테크, 인크. 항-ｖｅｇｆ 항체
CA2422881A1 (en) * 2000-10-13 2002-04-18 Uab Research Foundation Human anti-epidermal growth factor receptor single-chain antibodies
RU2430927C2 (ru) * 2000-10-20 2011-10-10 Тугаи Сейяку Кабусики Кайся Агонистическое соединение, способное специфически узнавать и поперечно сшивать молекулу клеточной поверхности или внутриклеточную молекулу
US7667004B2 (en) * 2001-04-17 2010-02-23 Abmaxis, Inc. Humanized antibodies against vascular endothelial growth factor
US20060073141A1 (en) * 2001-06-28 2006-04-06 Domantis Limited Compositions and methods for treating inflammatory disorders
US20050271663A1 (en) * 2001-06-28 2005-12-08 Domantis Limited Compositions and methods for treating inflammatory disorders
AU2003244817B2 (en) * 2002-06-28 2010-08-26 Domantis Limited Antigen-binding immunoglobulin single variable domains and dual-specific constructs
EP1558645B1 (en) * 2002-11-08 2011-07-27 Ablynx N.V. Stabilized single domain antibodies in pharmaceutical composition adapted for inhalation
EP1578801A2 (en) * 2002-12-27 2005-09-28 Domantis Limited Dual specific single domain antibodies specific for a ligand and for the receptor of the ligand
DE602004017726D1 (de) * 2003-06-30 2008-12-24 Domantis Ltd Pegylierte Single-domain-antikörper (dAb)
US20050106667A1 (en) * 2003-08-01 2005-05-19 Genentech, Inc Binding polypeptides with restricted diversity sequences
ATE485307T1 (de) * 2003-11-07 2010-11-15 Ablynx Nv Camelidae schwere ketten antikörper vhhs gegen epidermalen wachstumfaktor rezeptor (egfr) und ihre verwendung
US20090252681A1 (en) * 2005-10-11 2009-10-08 Ablynx N.V. Nanobodies and Polypeptides Against EGFR and IGF-IR

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2177950C2 (ru) * 1996-10-25 2002-01-10 Нексстар Фармасьютикалз, Инк. Комплексы нуклеиновых кислот - лигандов сосудистого эндотелиального фактора роста (vegf)
RU2003114746A (ru) * 2000-10-20 2004-12-20 Тугаи Сейяку Кабусики Кайся Модифицированное агонистическое антитело

Also Published As

Publication number Publication date
NO20082386L (no) 2008-08-27
AU2006323412A1 (en) 2007-06-14
BRPI0619463A2 (pt) 2013-01-08
CR10024A (es) 2008-09-22
CA2632417A1 (en) 2007-06-14
US20100056439A1 (en) 2010-03-04
MA30021B1 (fr) 2008-12-01
JP2009518024A (ja) 2009-05-07
KR20080077261A (ko) 2008-08-21
TW200804425A (en) 2008-01-16
EP1966242A1 (en) 2008-09-10
EA200801172A1 (ru) 2008-12-30
US20130041136A1 (en) 2013-02-14
WO2007066106A1 (en) 2007-06-14

Similar Documents

Publication Publication Date Title
EA013878B1 (ru) Лиганды, имеющие специфичность связывания в отношении рецептора эпидермального фактора роста (egfr) и/или сосудистого эндотелиального фактора роста (vegf), и способы их применения
EP4176896B1 (en) Matriptase and u-plasminogen activator substrates and other cleavable moieties and methods of use thereof
JP2021516960A (ja) Ｃｄ７３を標的とする抗体および抗体−薬物複合体、その製造方法と使用
EP4299589A1 (en) Anti-human cd73 antibody and use thereof
CA2960466C (en) Cancer cell-specific antibody, anticancer drug and cancer testing method
CN106459205A (zh) 包含半胱氨酸工程化抗体的轭合化合物
CN113527487A (zh) 抗人b7-h3的单克隆抗体及其应用
JP2019503709A (ja) ヒト化抗ｃｄ７３抗体
EA012622B1 (ru) Биспецифичные гибридные антитела с увеличенным периодом полувыведения из сыворотки
CN105349618B (zh) 三阴性乳腺癌标记物及其在诊断和治疗中的应用
KR20080090414A (ko) 세포 표면 표적에 대한 결합 특이성이 있는 이중 특이성리간드 및 이의 사용방법
CN112745392B (zh) 抗pd-l1/cd47双特异性抗体及其用途
JP7020656B2 (ja) 組織因子を標的とする抗体、その調製方法及びその使用
CN115768797B (zh) 抗b7-h3抗体及其制备和应用
WO2014193191A1 (ko) 항-vegf 항체 및 이를 포함하는 암 또는 신생혈관형성관련 질환의 예방, 진단 또는 치료용 약학 조성물
JP2018154641A (ja) 改変ａｘｌペプチド及び抗転移療法のａｘｌシグナル伝達阻害におけるその使用
CA2685182A1 (en) Osteopontin functional epitopes, monoclonal antibody against the epitopes and uses thereof
CN119698433A (zh) 抗cd28人源化单域抗体
EP3502141A1 (en) Antibody targeted to tissue factor, preparation method therefor, and use thereof
Wong et al. Development of a high-affinity anti-ROR1 variable region for broad anti-cancer immunotherapy
CN115558029B (zh) 靶向pd-1的双特异性抗体、及其制备和应用
CN120020149A (zh) Cldn6结合分子及其用途
JP2018529716A (ja) 癌幹細胞を阻害する組成物及び方法
CN119390838B (zh) 一种靶向ccr7的纳米抗体及其制备与应用
TW202535920A (zh) 程序性死亡配體1（pd-l1）嵌合抗原受體及其應用

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ KG MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): BY KZ RU